Loading company…
Menlo Park-based Recida Therapeutics develops anti-infective medicines for multidrug-resistant gram-negative bacterial infections.
Founded in 2016 and based in California, US, the company's lead program, RC-01, is an IND-stage LpxC inhibitor. It targets LpxC, an enzyme in Lipid A biosynthesis that gram-negative bacteria need to build the outer membrane they depend on to survive.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in